Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-3302-2026

PALACOS R+G pro 40; PALACOS R+G pro 80. Recall

PALACOS R+G pro 40; PALACOS R+G pro 80. Model/Catalog Number: 5081288; 5081289. Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix).

FDA recall Class II

Ongoing

FDA lists this Class II recall for PALACOS R+G pro 40; PALACOS R+G pro 80.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-3302-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Aug 20, 2026
FDA report date
Oct 7, 2026
Quantity in commerce
59,660 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

PALACOS R+G pro 40; PALACOS R+G pro 80. Model/Catalog Number: 5081288; 5081289. Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix).

Affected model & UDI checker

Search the exact identifiers published for Z-3302-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
5081288PALACOS R+G pro 40; PALACOS R+G pro 80.Check source noticeNot specified
Not specifiedPALACOS R+G pro 40; PALACOS R+G pro 80.Check source notice04260102136182
FDA code information

Lot Code: UDI-DI: 04260102136182; 04260102136212. All Batch Numbers. All Lot Numbers.

View the original FDA recall notice

Why was this product recalled?

Potential for monomer liquid leakage.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Heraeus Medical GmbH (Dental Division) take?

Heraeus Medical notified consignees on about 08/20/2026 via emailed letter. Consignees were informed of the issue and risk and were instructed to read the Correction Letter carefully and ensure that all relevant hospital departments are made aware of its contents, ensure that suitable eye protection is worn whenever the system is being operated, and complete and return the provided reply form. If any leakage is observed, do not continue to use the product. Instead, discard it with additional precautions, such as wearing double gloves (e.g. nitrile rubber), in accordance with internal hospital procedures and local waste disposal guidelines. Additionally, consignees were instructed to keep a copy of the provided response form with your records in case your organization is subject to a compliance audit.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology